Home Over Mibiton Mibiton Share Mibiton Solo Mibiton Science Deadlines Portfolio SMEs (MKB) Q&A Publicaties Agenda & Links  


Mibiton Nieuws en documenten
9-7-2010 Verbijstering na massaontslag Organon
1-7-2010 Skyline Diagnostics closes licensing agreement with TrovaGene Inc.
9-6-2010 Mibiton Jaarverslag 2009 aangeboden aan Willem Zwalve, directeur Agentschap.nl
3-6-2010 Merus Announces Publication of the Generation of Single, Clonal Cell lines
1-6-2010 Tweede call FASILIS vouchers geopend
27-5-2010 Masterclass BioBusiness start weer in oktober 2010
18-5-2010 Mibiton financiert de algenproductiefaciliteit van Feyecon BV en DNA synthese apparatuur van Flexgen
14-4-2010 Voorpublicatie interview F. Sybesma Jaarverslag 2009 'The Netherlands needs a new industrial policy'
31-3-2010 Prosensa initiates clinical development of PRO044 in an open label phase I/II study - Prosensa’s sec
29-1-2010 Merus closes EUR 21.7 million Series B financing and enters option agreement

De eerstvolgende deadline voor het indienen van investeringsaanvragen is donderdag 7 oktober 2010
 
Tot 15 september 2010 staat de Masterclass BioBusiness open voor aanmeldingen. 
 
Voor een overzicht van Life Sciences start-up support activiteiten zie: www.lifesciencesatwork.nl

 

Merus Announces Publication of the Generation of Single, Clonal Cell lines

3-6-2010
Utrecht, The Netherlands (June 2, 2010).
Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the  ‘Early View’ section of the journal Biotechnology and Bioengineering that demonstrate for the first time the feasibility of producing mixtures of human monoclonal antibodies (recombinant polyclonal antibodies) using a single, clonal production cell line. These data firmly establish the proprietary Oligoclonics™ technology of Merus as an attractive platform for the manufacturing of a new generation of more potent human antibody-based therapeutics.

“Is has long been known that mixtures of antibodies convey more potent biological effects than single monoclonal antibodies and that this could be translated into a therapeutic benefit” says Dr. Ton Logtenberg, CEO of Merus “but the lack of a stable, high yield production system based on a single cell line has hampered development of recombinant therapeutic polyclonal antibodies. What is particularly exciting about the data published is the novel demonstration that, using industry standard production technologies, cell lines secreting mixtures of antibodies could be robustly generated. We have found that cell line growth and IgG production characteristics are similar to those achieved with monoclonal antibodies and ratios of individual antibody species in the mixture remain constant, while maintaining high yields.  This platform will allow the cost-effective development and manufacturing of recombinant polyclonal antibodies with more potent clinical effects”. 

About Merus (www.merus.nl). Merus is a privately-held biopharmaceutical company building a pipeline of innovative human therapeutic antibody products. By using its proprietary technology platforms that include novel transgenic mice (MeMo™), Merus aims to produce highly potent human antibody-based drugs for the treatment of cancer, infectious and inflammatory diseases, whether as full-length bispecific antibodies (Biclonics™) or as recombinant polyclonal antibodies produced by a single cell (Oligoclonics™). 


Tags:

kleinere lettergrotere letterprint pagina

Home | Contact | Postbus 443 - 2260 AK Leidschendam - Loire 150 - 2491 AK Den Haag -
Telefoon + 31 (0)70 337 8780 - Fax + 31 (0)70 337 8737 - Email blom@mibiton.nl | Disclaimer    
Techniek en realisatie: www.easy-content.nl